The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
14/09/2024
ESMO Colloquium supported by Eli Lilly and Company
Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
- Welcome and introduction
Joyce O'Shaughnessy - Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer
Elgene Lim - Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy
Cristina Saura Manich - HR(+)/HER2(-) advanced breast cancer: How can biology inform us on optimising the precision therapeutic strategies in 1L and 2L post progression after endocrine+CDK4/6i?
Philippe Aftimos - A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition
Joyce O'Shaughnessy - Q&A and discussion
- Concluding remarks
Cristina Saura Manich
16/09/2024
ESMO Colloquium supported by Novocure
The role of alternating electric fields in the therapeutic management of patients with advanced non-small cell lung cancer
- Welcome and introduction
Ticiana Leal - Alternating electric fields in cancer therapy: Mode of action and principles of cytotoxicity
Carsten Hagemann - Clinical evidence for efficacy & safety of electric fields therapeutic applications for patients with advanced non-small cell lung cancer
Ticiana Leal - Emerging clinical evidence on the efficacy of electric fields in controlling sanctuary metastatic site
Minesh Mehta - Research insights in future developments of alternating electric field applications in oncology and potential for combination with systemic agents and irradiation
Gerben Borst - Q&A and discussion
- Concluding remarks
Gerben Borst